Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

GM2-KLH vaccine

Known as: GM2-KLH, GM2-KLH ganglioside, KLH-conjugated GM2 Ganglioside Vaccine 
A cancer vaccine consisting of GM2 ganglioside, a melanoma-specific antigen, conjugated with the immunostimulant keyhole limpet hemocyanin… 
National Institutes of Health

Related topics

Related topics

1 relation
GM2-KLH vaccine/QS21

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.
PURPOSE The GM2 ganglioside is an antigen expressed in the majority of melanomas. The GM2-KLH/QS-21 vaccine induces high… 
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2001
Highly Cited
2001
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup…
PURPOSE Vaccine alternatives to high-dose interferon alfa-2b therapy (HDI), the current standard adjuvant therapy for high-risk… 
2001
2001
The EORTC melanoma group translational research program on prognostic factors and ultrastaging in association with the adjuvant therapy trials in stage II and stage III melanoma. European…
Last year the Melanoma Group of the European Organization for Research and Treatment of Cancer (EORTC-MG) completed accrual (1418… 
Highly Cited
2000
Highly Cited
2000
Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
In a previous randomized Phase III trial (P. O. Livingston et al, J. Clin. Oncol., 12: 1036-1044, 1994), we demonstrated that… 
  • table 2
  • table 1
  • figure 1
  • figure 2
  • figure 4
Highly Cited
2000
Highly Cited
2000
Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.
Immunization with GMK vaccine (G(M2) ganglioside conjugated to keyhole limpet hemocyanin mixed with QS-21 adjuvant) induces anti… 
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Review
1998
Review
1998
Ganglioside vaccines with emphasis on GM2.
Gangliosides are neuraminic acid-containing glycosphingolipids that are anchored into the cell membrane lipid bilayer by… 
Highly Cited
1998
Highly Cited
1998
QS-21: a water-soluble triterpene glycoside adjuvant.
QS-21 is a purified immunological adjuvant derived from a natural source, the bark of the tree Quillaja saponaria. It is a water… 
Highly Cited
1997
Highly Cited
1997
Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies
Abstract Natural IgM antibodies against the melanoma cell-surface ganglioside GM2, and IgM antibodies induced by vaccination with… 
  • figure 1
  • figure 2
Highly Cited
1995
Highly Cited
1995
GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
The cell surface gangliosides GM2, GD2, and GD3 are often overexpressed in malignant melanoma. We have shown previously that… 
Review
1995
Review
1995
Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside‐KLH Conjugate Vaccines
Gangliosides are neuraminic acid containing glycosphingolipids that are anchored into the lipid bilayer of the plasma membrane by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE